Use of lipoteichoic acid-T for pleurodesis in malignant pleural effusion: a phase I toxicity and dose-escalation study. (Q53209076)

12 May 2018

title

Use of lipoteichoic acid-T for pleurodesis in malignant pleural effusion: a phase I toxicity and dose-escalation study. (English)

1 reference

12 May 2018

malignant pleural effusion

main subject

1 reference

1

1 reference

12 May 2018

author name string

Helen E Davies

2

1 reference

12 May 2018

Marc Salzberg

3

1 reference

12 May 2018

Peter Truog

4

1 reference

12 May 2018

Rachel Midgely

5

1 reference

12 May 2018

David Kerr

6

1 reference

12 May 2018

Colin Clelland

7

1 reference

12 May 2018

Emma L Hedley

8

1 reference

12 May 2018

Y C Gary Lee

9

1 reference

12 May 2018

Robert J O Davies

10

1 reference

12 May 2018

publication date

3 September 2008

1 reference

12 May 2018

Lancet Oncology Commission

published in

1 reference

12 May 2018

volume

9

1 reference

12 May 2018

issue

10

1 reference

12 May 2018

page(s)

946-952

1 reference

12 May 2018

Management of malignant pleural effusions

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970205-5

7 January 2021

Systemic distribution of talc

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970205-5

7 January 2021

BTS guidelines for the management of malignant pleural effusions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970205-5

7 January 2021

Pleurodesis practice for malignant pleural effusions in five English-speaking countries: survey of pulmonologists.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970205-5

7 January 2021

Talcage by medical thoracoscopy for primary spontaneous pneumothorax is more cost-effective than drainage: a randomised study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970205-5

7 January 2021

Talc poudrage versus talc slurry in the treatment of malignant pleural effusion. A prospective comparative study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970205-5

7 January 2021

Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970205-5

7 January 2021

Serious complications with talc slurry pleurodesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970205-5

7 January 2021

Predictors of acute lung injury and severe hypoxemia in patients undergoing operative talc pleurodesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970205-5

7 January 2021

Thoracoscopy talc poudrage : a 15-year experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970205-5

7 January 2021

Respiratory failure following talc pleurodesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970205-5

7 January 2021

Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970205-5

7 January 2021

Innate sensors for Gram-positive bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970205-5

7 January 2021

Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970205-5

7 January 2021

A comparison of intracavitary talc and tetracycline for the control of pleural effusions secondary to breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970205-5

7 January 2021

Pleurodesis using talc slurry

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970205-5

7 January 2021

A prospective, randomised study comparing the efficacy of talc slurry and bleomycin in the treatment of malignant pleural effusions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970205-5

7 January 2021

A comparative study of pleurodesis using talc slurry and bleomycin in the management of malignant pleural effusions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970205-5

7 January 2021

Prospective randomized trial of silver nitrate vs talc slurry in pleurodesis for symptomatic malignant pleural effusions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970205-5

7 January 2021

Pleurodesis in recurrent pleural effusions: a randomized comparison of a classical and a currently popular drug

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970205-5

7 January 2021

Acute pneumonitis with bilateral pleural effusion after talc pleurodesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970205-5

7 January 2021

Talc-induced expression of C-C and C-X-C chemokines and intercellular adhesion molecule-1 in mesothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970205-5

7 January 2021

Talc-induced inflammation in the pleural cavity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970205-5

7 January 2021

Evidence that mesothelial cells regulate the acute inflammatory response in talc pleurodesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970205-5

7 January 2021

Pleural mesothelial cells mediate inflammatory and profibrotic responses in talc-induced pleurodesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970205-5

7 January 2021

Transforming growth factor-beta induces collagen synthesis without inducing IL-8 production in mesothelial cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970205-5

7 January 2021

Comparing transforming growth factor-beta2, talc and bleomycin as pleurodesing agents in sheep.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970205-5

7 January 2021

Transforming growth factor beta2 induced pleurodesis is not inhibited by corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970205-5

7 January 2021

Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970205-5

7 January 2021

Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970205-5

7 January 2021

Intrapleural cisplatin and OK432 therapy for malignant pleural effusion caused by non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970205-5

7 January 2021

Efficacious pleurodesis with OK-432 and doxorubicin against malignant pleural effusions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970205-5

7 January 2021

Comparison of OK-432 and mitomycin C pleurodesis for malignant pleural effusion caused by lung cancer. A Randomized Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970205-5

7 January 2021

10.1016/S1470-2045(08)70205-5

Identifiers

DOI

1 reference

12 May 2018

1 reference

12 May 2018